Tellgen Corporation (300642.SZ) has officially announced that its controlling subsidiaries, Jiangxi Tellgen Life Science Technology Co., Ltd. and Shanghai Maishi Biotechnology Co., Ltd., have recently secured medical device registration certificates from the Jiangxi Medical Products Administration and the Shanghai Medical Products Administration, respectively.

The newly approved products include the fully automated flow fluorescence luminescence immunoassay analyzer, available in models TESMIF5000 and TESMIF5000M, as well as a four-item anti-epileptic drug concentration assay kit utilizing liquid chromatography-tandem mass spectrometry methodology.

These regulatory clearances mark a significant milestone for the company's subsidiaries, expanding their product portfolios in the in-vitro diagnostics sector and reinforcing their market presence across the region.